ArticleBlood2025

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.

Carolin S Escherich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.